300482 Stock Overview
Guangzhou Wondfo Biotech Co.,Ltd, a biological company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions.
Guangzhou Wondfo Biotech Co.,Ltd Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥29.33|
|52 Week High||CN¥71.00|
|52 Week Low||CN¥28.33|
|1 Month Change||-10.22%|
|3 Month Change||-30.32%|
|1 Year Change||-31.79%|
|3 Year Change||-21.87%|
|5 Year Change||-6.19%|
|Change since IPO||495.77%|
Recent News & Updates
|300482||CN Medical Equipment||CN Market|
Return vs Industry: 300482 underperformed the CN Medical Equipment industry which returned -23% over the past year.
Return vs Market: 300482 underperformed the CN Market which returned -19.2% over the past year.
|300482 Average Weekly Movement||4.5%|
|Medical Equipment Industry Average Movement||5.9%|
|Market Average Movement||5.8%|
|10% most volatile stocks in CN Market||9.2%|
|10% least volatile stocks in CN Market||3.8%|
Stable Share Price: 300482 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 300482's weekly volatility (5%) has been stable over the past year.
About the Company
|1992||3,411||Wen Mei Li||https://www.wondfo.com.cn|
Guangzhou Wondfo Biotech Co.,Ltd, a biological company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provides blood gas, optical coagulation, and dry chemistry analyzers.
Guangzhou Wondfo Biotech Co.,Ltd Fundamentals Summary
|300482 fundamental statistics|
Is 300482 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|300482 income statement (TTM)|
|Cost of Revenue||CN¥2.57b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||2.83|
|Net Profit Margin||22.69%|
How did 300482 perform over the long term?See historical performance and comparison